drugset / Trial / NCT00455494

Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial

NCT00455494

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.

Timeline

Start
2005-01
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AQ-13 Small molecule 700 mg

Indications